BioSpace News Archive

Apollomics Inc., a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market.

Altrix Bio, a leading early-stage biotech startup, announces the issuance of US Patent 11,433,094, on September 6, 2022, for the proprietary compound, LuCI™, a novel agent for the treatment of obesity-associated metabolic disorders.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking place virtually on September 21-22, 2022.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC (“Talem”), has shared positive results of a new study conducted by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), that has shown the continued resilience of PolyTope® TATX-03.

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today provided an update on its research and development programs for its expanded portfolio of immuno-oncology assets, and outlined its forward-looking clinical development goals for the next two years.

We are pleased to announce World Cord Blood Day 2022 (WCBD 2022) will take place on November 15th, featuring a free online medical conference and educational events worldwide.

Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”) chief executive officer Stephen Croskrey will be taking part in a high-level Summit on Biotechnology & Biomanufacturing for the American Bioeconomy, being hosted today by the White House Administration.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based polio testing.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research (AACR) Special Conference for Pancreatic Cancer.

Bolstering its commitment to providing researchers with powerful tools to discover more about biology and advance medicine, global genomics solutions provider Integrated DNA Technologies (IDT) is expanding access to its customization options for the Alt-R™ Custom CRISPR gRNA Libraries.